2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the ASCO Annual Meeting from June 4-8, 2021. The following tables include the oral and poster presentations containing DCTD staff co-authors.

Oral Sessions

Title	Abstract
ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) +/- lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS	7503
Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols	10007
Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial	10008
P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE)	11503
NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma	11506

Poster Presentations

(P=DCTD Presenter; *Poster Discussion Session)

Title	Abstract
NCI’s national treatment trial networks: Experience and adaptations during COVID-19	1562
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-MATCH (EAY131) subprotocol U	3087
Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors	3088
Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS) P: Larissa Korde, MD, MPH	6565
Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS)	6566
*National Cancer Institute (NCI) implementation of the American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) broadening clinical trials eligibility criteria P: Andrea Denicoff, RN, MS, ANP	6518
Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study	8563
Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC)	10037
Minding the gap: Gynecologic oncology practices differ by gender	11011
*Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS) P: Abdul Rafeh Naqash, MD	11519
A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO)	TPS2676
S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma	TPS9585